Q.68 Who among the following scientists was the pioneer in development of
chemotherapy?
(A) Elie Metchnikoff
(B) Robert Koch
(C) Paul Ehrlich
(D) Ronald Ross

Paul Ehrlich pioneered the development of chemotherapy through his discovery of Salvarsan, the first targeted chemical treatment for syphilis. He is widely recognized as the “Father of Chemotherapy” for introducing the concept of “magic bullets” that selectively kill pathogens.​

Option Analysis

Each option represents a Nobel laureate in medicine, but only one advanced chemotherapy.

• (A) Elie Metchnikoff: Discovered phagocytosis, the process where immune cells engulf pathogens, earning the 1908 Nobel Prize in Physiology or Medicine (shared with Ehrlich) for innate immunity work. His contributions focused on cellular immunity, not chemical treatments.​

• (B) Robert Koch: Established germ theory by identifying pathogens for anthrax, tuberculosis, and cholera; developed Koch’s postulates and bacteriology techniques like agar media. He advanced microbiology but did not pioneer chemotherapy.​

• (C) Paul Ehrlich: Developed Salvarsan (arsphenamine) in 1909 as the first synthetic chemotherapeutic agent against syphilis bacteria, introducing receptor-based targeting. His side-chain theory and systematic screening of compounds founded modern chemotherapy.​

• (D) Ronald Ross: Discovered malaria transmission via Anopheles mosquitoes in 1897, earning the 1902 Nobel Prize; advanced vector control but contributed nothing to chemotherapy.​

Correct Answer: (C) Paul Ehrlich​

Introduction to Chemotherapy Pioneer

The pioneer in development of chemotherapy, Paul Ehrlich, revolutionized medicine by creating targeted chemical drugs like Salvarsan for syphilis treatment. This breakthrough shifted disease therapy from serums to synthetic agents, influencing cancer and antimicrobial treatments today. For CSIR NET aspirants, understanding Ehrlich’s role versus contemporaries clarifies key historical contributions.​

Paul Ehrlich: Father of Chemotherapy

Ehrlich coined “chemotherapy” and envisioned “magic bullets”—molecules binding specifically to pathogens via cell receptors. In 1909, after screening 606 compounds, he developed Salvarsan (compound 606), the first effective syphilis cure, minimizing host damage. His 1908 Nobel Prize (shared for immunity) and staining techniques laid groundwork for pharmacology.​

Contributions of Other Scientists

While all options advanced medicine, none matched Ehrlich in chemotherapy:

These distinctions highlight Ehrlich’s unique chemical therapy innovation.​

Legacy in Modern Medicine

Ehrlich’s receptor theory underpins targeted therapies like monoclonal antibodies and precision oncology. His work birthed antimicrobial chemotherapy, saving millions from infections. CSIR NET questions often test this milestone in biotechnology history.​